[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100554367":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":23,"centralContacts":27,"locations":36,"responsibleParty":68,"collaborators":70,"id":84,"slug":10,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":85,"sex":90,"minAge":91,"maxAge":10,"enrollmentInfo":92,"targetDuration":10,"studyType":95,"phases":10,"briefSummary":96,"conditions":97,"keywords":104,"overallStatus":51,"whyStopped":10,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},{"fullName":5,"class":6},"Universidade do Porto","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Upadatacinib Arm",null,"Patients exposed to upadacitinib (Rinvoq™)",[13],"Drug: Upadacitinib",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Upadacitinib","Exposure to upadacitinib (Rinvoq™) in its different formulations approved by the Portuguese regulatory authority (15, 30, or 45mg extended-release tablets).",[9],[21,22],"Rinvoq","ATC 200000041628",[24],{"name":25,"affiliation":5,"role":26},"Inês Ribeiro Vaz, PharmD, MPH, PhD","PRINCIPAL_INVESTIGATOR",[28,32],{"name":25,"role":29,"phone":30,"phoneExt":10,"email":31},"CONTACT","+ 351220426952","inesvaz@med.up.pt",{"name":33,"role":29,"phone":34,"phoneExt":10,"email":35},"Renato Ferreira da Silva, PharmD","+351220426913","rsilva@med.up.pt",[37,49,62],{"facility":38,"status":39,"city":40,"state":10,"zip":41,"country":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":10},"Unidade Local de Saúde de Santo António, E.P.E.","ACTIVE_NOT_RECRUITING","Porto","4050-366","Portugal",{"type":44,"coordinates":45},"Point",[46,47],-8.61097,41.1485,{"lat":47,"lon":46},{"facility":50,"status":51,"city":40,"state":10,"zip":52,"country":42,"cosmosGeoPoint":53,"geoPoint":55,"contacts":56},"Unidade Local de Saúde de São João, E.P.E.","RECRUITING","4200-319",{"type":44,"coordinates":54},[46,47],{"lat":47,"lon":46},[57,61],{"name":58,"role":29,"phone":59,"phoneExt":10,"email":60},"Manuela Pinto, PharmD","+351225512143","manuela.milne@ulssjoao.min-saud.pt",{"name":58,"role":26,"phone":10,"phoneExt":10,"email":10},{"facility":63,"status":39,"city":40,"state":10,"zip":64,"country":42,"cosmosGeoPoint":65,"geoPoint":67,"contacts":10},"Unidade Local de Saúde de Gaia\u002FEspinho, E.P.E.","4434-502",{"type":44,"coordinates":66},[46,47],{"lat":47,"lon":46},{"type":69,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[71,74,76,79,80,82],{"name":72,"class":73},"INFARMED - Autoridade Nacional do Medicamento e Produtos de Saúde, I.P.","UNKNOWN",{"name":75,"class":73},"Unidade de Farmacovigilância do Porto",{"name":77,"class":78},"Unidade Local de Saúde São João","OTHER_GOV",{"name":38,"class":73},{"name":81,"class":6},"Unidade Local de Saude de Gaia e Espinho EPE",{"name":83,"class":73},"RISE Health","100554367",false,"NCT06498167","Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)","LOOK-UP","Inclusion Criteria:\n\n* Prescription of Rinvoq™ from January 1, 2024;\n* 18 years of age or older at the time of recruitment; and\n* Expressed consent to participate in the study.\n\nExclusion Criteria:\n\n* They have any degree of cognitive impairment that prevents them from responding to a questionnaire administered by telephone;\n* They are participating in a phase I, II, or III clinical trial;\n* They have a life expectancy of less than 1 month; or\n* They do not have a valid telephone contact.","ALL","18 Years",{"count":93,"type":94},150,"ESTIMATED","OBSERVATIONAL","The LOOK-UP is an investigator-initiated clinical study with the aim of monitoring the post-marketing safety of the medicine Rinvoq™ (upadacitinib), which is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease. The Marketing Authorisation Holder is AbbVie Deutschland GmbH \\& Co. KG.",[98,99,100,101,102,103],"Inflammatory Disease","Drug Side Effect","Drug Use","Adverse Drug Event","Adverse Drug Reaction","Safety Issues",[17,21,105,106,107,108,109,110,111,112,113],"Rheumatoid arthritis","Psoriatic arthritis","Axial spondyloarthritis","Atopic dermatitis","Ulcerative colitis","Crohn's disease","Pharmacovigilance risk","Drug safety monitoring","Patient Safety","2024-07-12",{"date":116,"type":117},"2024-07-15","ACTUAL",{"date":119,"type":117},"2024-07-01",{"date":121,"type":94},"2024-12-31",{"name":5,"class":6},3]